Erectile Dysfunction Market 2019 | In-depth Analysis by Top Players Meda Pharmaceuticals, Inc., Coloplast, Global Life Technologies, Reflexonic, LLC, Augusta Medical System, Boston Scientific Corporation, Vivus, Inc.

Erectile dysfunction is known as the medical condition of penis, a recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities. It is most probably an age-related factor, progressive condition, affecting some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years, and with the increase in the age, severity of erectile dysfunction also increase with a ratio of about 5% at the age of 50 to 15% at 70 years. Even though this is a common condition, related to both age and secondary medical conditions like diabetes, hypertension, dyslipedemia, depression and cardiovascular disease, there were treatments conducted in the past by mostly andrologists, urologists and sex therapists. There has been a revolutionary introduction of oral drug therapy to treat erectile dysfunction and the enormous studies concerning erectile dysfunction has led to a paradigm shift in erectile dysfunction treatment.

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/200

According to study conducted by Canadian Institute of Health Research, there were about 4,000 Canadian men between the age 40 and 88 years, nearly half of them had erectile dysfunction. It was about approximately two times more usual in men with cardiovascular disease and four times more usual among men suffering with any kind of diabetes. Increase in the number of erectile dysfunction cases has led to an increase in the Cialis drugs, proportionally boost the erectile dysfunction market.

The global erectile dysfunction market was valued at US$ 4,129.5 million in 2015 and is expected to witness a CAGR of 0.2% during the forecast period (2016 – 2024).

Market Dynamics

North America and Asia Pacific are the largest markets for erectile dysfunction products, as these regions have the highest prevalence of erectile dysfunction. For instance in the year 2012, according to The Massachusetts study, approximately 19,372 new cases of erectile dysfunction in Massachusetts and more than 721,615 cases in the United States yearly. China has a prevalence percentage of about 42.3 in the year 2011. There are many studies conducted to develop medication and medical devices to treat erectile dysfunction. According to the National Institutes of Health, over 30 million men over 75 years of age suffer from erectile dysfunction in the U.S. The Multinational Survey on the Aging Male (MSAM) study conducted in the U.S. and in European countries such as France, Germany, Italy, Netherlands, Spain, and the U.K. arrived at an unexplained relationship between lower urinary tract symptoms and sexual dysfunction in over 12 thousand men in the age group of 50-80 years. Of the 83% of the male population that was surveyed, who claimed to be sexually-active all the time, overall prevalence of lower urinary tract symptoms was 90%, with an overall incidence of erectile dysfunction pegged at 50%, and 10% of patients reported a complete absence of erection. Moreover, the overall incidence of ejaculation disorders was 46%.

50 open clinical studies presently, to treat erectile dysfunction to boost the erectile dysfunction market

According to pharma industry news, in 2012, Viagra drugs dominated the erectile dysfunction market with an approximate market share of about 45% in terms of revenue. Though, the market value for Viagra has declined due to its patent expiry in European countries by 2013, however the other pharmaceutical companies has then shown a keen interest in developing the generic Viagra drug for erectile dysfunction treatment. In-spite the patent loss, US market maintained a continual growth and is expected to dominate the erectile dysfunction market by 2020. The other prominent drug after Viagra is Cialis which holds the second largest market share globally. At present the market for Cialis drug is growing exceptionally well, however there can be an expected decline of Cialis’s drug market share as the patent expiration is due in mid of 2017. Furthermore, one of the Bayer’s erectile dysfunction drug, Levitra/Staxyn is expected to lose its patent by 2018 and is thus expected to contribute to the declining market revenue for Erectile Dysfunction Market. However, as there about 50 drug molecules under clinical trials, among which few drugs are expected to launch by 2018 and 2019 owing to increase in Erectile Dysfunction Market proportionally.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/200

Key Players

Key companies covered as a part of this study include Meda Pharmaceuticals, Inc., Coloplast, Global Life Technologies, Reflexonic, LLC, Augusta Medical System, Boston Scientific Corporation, and Vivus, Inc.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.